SCHEDULE: Camac Partners Discloses 5.3% Stake in Cryo-Cell

Camac Partners and affiliates have disclosed a 5.3% beneficial ownership stake in Cryo-Cell International, Inc., citing undervaluation and plans for strategic engagement.

Summary

• Camac Partners, Camac Capital, Camac Fund, LP, and Eric Shahinian (collectively, the "Reporting Persons") have filed a Schedule 13D, disclosing beneficial ownership of 430,900 shares of Cryo-Cell International, Inc. common stock.
• This represents approximately 5.3% of the Issuer's 8,055,150 shares outstanding as of November 30, 2026.
• The shares were acquired with working capital, including potential margin loans, for an aggregate purchase price of approximately $1,354,672.
• The Reporting Persons believe the securities were undervalued and represent an attractive investment opportunity.
• They intend to engage in discussions with Cryo-Cell's management and Board of Directors regarding corporate governance, Board composition, expenditure levels, asset monetization, and return of capital to shareholders.
• They may also adjust their position by buying or selling additional shares or entering into hedging transactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for Cryo-Cell International, as it signals an engaged investor group believes the stock is undervalued and intends to advocate for shareholder value creation, potentially leading to strategic improvements.

Positives

• A significant institutional investor, Camac Partners, has identified Cryo-Cell International, Inc. as an attractive investment opportunity, believing its securities are undervalued.
• The investor group plans to engage with management and the Board to discuss strategies for enhancing shareholder value, including corporate governance, asset monetization, and capital returns.

Risks

• The Reporting Persons may increase or decrease their positions, which could impact share price volatility.
• Their investment strategy includes potential use of margin loans, which carries inherent financial risk.
• There is no guarantee that discussions with management and the Board will lead to desired changes or improved shareholder value.

Future Outlook

The Reporting Persons intend to review their investment periodically and may engage in discussions with Cryo-Cell's management and Board concerning corporate governance, Board composition, expenditure levels, monetization of assets, and return of capital to shareholders. They may also adjust their position in the Issuer through further purchases or sales or by entering into hedging transactions.

Management Comments

• "The Reporting Persons purchased the securities of the Issuer reported herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity."
• "The Reporting Persons intend to review their investments in the Issuer on a periodic basis and may from time to time engage in communications and discussions with management and the Board of Directors of the Issuer... concerning, among other things, Board composition and corporate governance, levels of expenditures, monetization of all of the company's assets, and return of capital to shareholders."

Industry Context

StockSavvy.ai notes that activist investor filings like this Schedule 13D often signal potential for strategic shifts or increased shareholder pressure within the biotechnology or healthcare services sector, particularly for companies perceived as undervalued or underperforming. Such filings can draw market attention to the issuer and potentially catalyze changes in corporate strategy or governance.

Comparison to Industry Standards

• The 5.3% stake is a significant initial position for an activist investor group, often sufficient to initiate dialogue and exert influence, comparable to stakes taken by other activist funds in small-to-mid cap companies in the healthcare sector, such as Starboard Value's historical engagements with various healthcare firms or Carl Icahn's past positions.
• The stated intent to discuss corporate governance, asset monetization, and capital returns aligns with common activist playbooks seen across industries, aiming to unlock shareholder value, similar to strategies employed by funds like Elliott Management or ValueAct Capital in their respective target companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic initiatives, asset monetization, and capital returns if the activist investor's engagement is successful. Increased scrutiny on management performance.
• Management/Board: Increased pressure to perform and potentially adapt to new strategic directions proposed by the activist investor.

Next Steps

• Reporting Persons may increase or decrease their positions in Cryo-Cell International, Inc.
• Reporting Persons may enter into transactions that increase or hedge their economic exposure to the securities.
• Reporting Persons intend to engage in communications and discussions with Cryo-Cell's management and Board of Directors.
• Reporting Persons may review or reconsider their position and/or change their purpose and/or formulate plans or proposals.

Key Dates

Recommendation

The disclosure of a significant activist stake by Camac Partners suggests potential for future strategic actions that could unlock value, but these are not yet concrete. While the investor believes the stock is undervalued, the immediate impact is speculative. A "hold" recommendation is appropriate as investors await further developments from the engagement between Camac Partners and Cryo-Cell's management and Board.

Keywords

Cryo-Cell International, Camac Partners, Schedule 13D, Beneficial Ownership, Activist Investor, Corporate Governance, Shareholder Value, Investment Opportunity, Undervalued Stock, Equity Stake